Background: Tumor vascular endothelial growth factor (VEGF) is a key angiogenic factor and may have an impact on tumor progression and response to chemotherapy. The insulin-like growth factor (IGF) system is related to cell proliferation and tumor growth. However, there is limited available data regarding the clinical and prognostic significance of VEGF or IGF-1 in advanced gastric cancer. The aim of this study was to evaluate the prognostic significance of serum VEGF and IGF-1 levels in advanced gastric cancer patients who were treated with oxaliplatin/5-fluorouracil (FOLFOX). Methods: The study population consisted of 100 advanced gastric cancer patients (median age 56 years). Patients were treated with oxaliplatin 85 mg/m2 as a 2-hour infusion on day 1 plus leucovorin 20 mg/m2 over 10 min, followed by a 5-fluorouracil (5-FU) bolus 400 mg/m2 and 22 h of continuous infusion of 600 mg/m2 on days 1–2. Treatment was repeated in 2-week intervals. The levels of serum VEGF and IGF-1 were measured using enzyme-linked immunoassays. Results: There was a significant correlation between the serum level of VEGF and Lauren’s classification (p = 0.030) and previous operations (p = 0.010). IGF-1 was associated with the number of metastases (p = 0.012). The median level of serum VEGF was decreased after FOLFOX chemotherapy (p = 0.034). However, none of the measured serum markers were significantly correlated with response. In univariate analysis, overall survival (p < 0.001) was significantly shorter in patients with high serum levels of VEGF. Multivariate analysis revealed that VEGF was an independent factor for overall survival (HR 2.221; 95% CI 1.377–3.583, p = 0.001). Furthermore, IGF-1 had no significant influence on the clinical outcome. Conclusion: A high level of serum VEGF is an independent prognostic factor in patients with advanced gastric cancer treated with chemotherapy. This may help to identify the patients who are more sensitive to the FOLFOX regimen.

Keywords:
Vascular endothelial growth factor, Insulin-like growth factor-1, FOLFOX, Gastric carcinoma
1.
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
2.
Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, Lee JS: Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 2011;43:1–11.
3.
Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903–2909.
4.
Pasini F, Fraccon AP, G De Mazoni G: The role of chemotherapy in metastatic gastric cancer. Anticancer Res 2011;31:3543–3554.
5.
Oh SY, Kwon HC, Seo BG, Kim SH, Kim JS, Kim HJ: A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncol 2007;46:336–341.
6.
Kim YS, Hong J, Sym SJ, Park SH, Park J, Cho EK, Lee JH, Shin DB: Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer. Cancer Res Treat 2010;42:24–29.
7.
Xiang XJ, Zhang L, Qiu F, Yu F, Zhan ZY, Feng M, Yan J, Zhao JG, Xiong JP: A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer. Chemotherapy 2012;58:1–7.
8.
Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4–25.
9.
Eroglu A: Serum levels of vascular endothelial growth factor in gastric cancer patients. J Surg Oncol 2011;104:222.
10.
Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T: Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol 1997;15:826–832.
11.
Peng L, Zhan P, Zhou Y, Fang W, Zhao P, Zheng Y, Xu N: Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep 2012;39:9473–9484.
12.
Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858–863.
13.
Chen J, Li T, Wu Y, He L, Zhang L, Shi T, Yi Z, Liu M, Pang X: Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2011;137:1799–1812.
14.
Poon RT, Fan ST, Wong J: Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207–1225.
15.
Vidal O, Metges JP, Elizalde I, Valentini M, Volant A, Molina R, Castells A, Pera M: High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg 2009;96:1443–1451.
16.
Karayiannakis AJ, Syrigos KN, Zbar A, Baibas N, Polychronidis A, Simopoulos C, Karatzas G: Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 2002;131:548–555.
17.
Kitamura M, Toi M, Arai K, Iwasaki Y, Suzuki H, Matsuo K: Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients. Oncol Rep 1998;5:1419–1424.
18.
Seo HY, Park JM, Park KH, Kim SJ, Oh SC, Kim BS, Kim YH, Kim JS: Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients. Jpn J Clin Oncol 2010;40:1147–1153.
19.
Le Roith D: Seminars in medicine of the Beth Israel Deaconess Medical Center: insulin-like growth factors. N Engl J Med 1997;336:633–640.
20.
Samani AA, Yakar S, LeRoith D, Brodt P: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20–47.
21.
Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12:159–169.
22.
LeRoith D, Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127–137.
23.
Lee DY, Kim SJ, Lee YC: Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Korean Med Sci 1999;14:401–404.
24.
Han JY, Choi BG, Choi JY, Lee SY, Ju SY: The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. Lung Cancer 2006;54:227–234.
25.
Pham TM, Fujino Y, Kikuchi S, Tamakoshi A, Yatsuya H, Matsuda S, Yoshimura T: A nested case-control study of stomach cancer and serum insulin-like growth factor (IGF)-1, IGF-2 and IGF-binding protein (IGFBP)-3. Eur J Cancer 2007;43:1611–1616.
26.
Lee DY, Yang DH, Kang CW, Kim SJ, Joo CU, Cho SC, Kim JS: Serum insulin-like growth factors (IGFs) and IGF binding protein (IGFBP)-3 in patients with gastric cancer: IGFBP-3 protease activity induced by surgery. J Korean Med Sci 1997;12:32–39.
27.
Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007;18:504–509.
28.
Seo BG, Kwon HC, Oh SY, Lee S, Kim SG, Kim SH, Han H, Kim HJ: Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Oncol Rep 2009;22:127–136.
29.
Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D: Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002;62:1030–1035.
30.
Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM: Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 1998;58:4008–4014.
31.
Stoeltzing O, Liu W, Reinmuth N, Fan F, Parikh AA, Bucana CD, Evans DB, Semenza GL, Ellis LM: Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 2003;163:1001–1011.
32.
Li H, Adachi Y, Yamamoto H, Min Y, Ohashi H, Ii M, Arimura Y, Endo T, Lee CT, Carbone DP, Imai K, Shinomura Y: Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45. Cancer 2011;117:3135–3147.
33.
Shitara K, Ito S, Misawa K, Ito Y, Ito H, Hosono S, Watanabe M, Tajima K, Tanaka H, Muro K, Matsuo K: Genetic polymorphism of IGF-I predicts recurrence in patients with gastric cancer who have undergone curative gastrectomy. Ann Oncol 2012;23:659–664.
34.
Izycki T, Chyczewska E, Naumnik W, Talalaj J, Panek B, Ossolinska M: Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy. Exp Oncol 2004;26:316–319.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.